These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5706063)

  • 1. Combined effect in the radiologic and immunologic treatment of a malignant homograft.
    Kano E
    Acta Radiol Ther Phys Biol; 1968 Jun; 7(3):209-29. PubMed ID: 5706063
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance and susceptibility to tumours. 3. Effect of some derivatives from immunized animals on the Bo4 and Ehrlich carcinomas.
    Dvorák R; Chlumecký J
    Neoplasma; 1969; 16(6):613-24. PubMed ID: 5369028
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antineoplastic immunological reactions in animals with Ehrlich's carcinoma].
    Bergamini G; D'Acunzo L; Fazio G; Giudici G
    Riv Patol Clin Sper; 1967; 8(4):477-88. PubMed ID: 5605966
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of purine-protein conjugates on the Ehrlich ascites tumor in mice.
    Lachman C; Cohen S
    Cancer Res; 1970 Feb; 30(2):439-46. PubMed ID: 5441091
    [No Abstract]   [Full Text] [Related]  

  • 5. Transplantability and antigenicity of two sublines of the TA3 tumor.
    Sanford BH; Codington JF; Jeanloz RW; Palmer PD
    J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunoradioactive agent against cancer.
    Ghose T; Cerini M; Carter M; Nairn RC
    Br Med J; 1967 Jan; 1(5532):90-3. PubMed ID: 6015636
    [No Abstract]   [Full Text] [Related]  

  • 7. Serological studies of antigenic changes occurring in two lines of Ehrlich's ascites tumor after long periods of cultivation in vitro.
    Monti-Bragadin C; Kieler J
    Eur J Cancer (1965); 1968 Jul; 4(3):255-61. PubMed ID: 5760800
    [No Abstract]   [Full Text] [Related]  

  • 8. Complement factors and the growth of Ehrlich's carcinoma.
    Thunold S; Horseide V; Hartveit F
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1973 Jun; 81(3):373-81. PubMed ID: 4130388
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro measurement of cytotoxic antibodies in mouse-immune sera against mouse ascites tumor cells.
    Eng CP; Tolbert WR; Harnaha JB; Concannon JP
    Can J Microbiol; 1974 Dec; 20(12):1681-8. PubMed ID: 4479949
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of murine C-type viruses. IV. The virus produced by Ehrlich tumor cells and it hybrids with mouse L cells.
    Grundner G; Fenyö EM; Klein E
    Int J Cancer; 1974 Mar; 13(3):420-27. PubMed ID: 4362614
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of immune organ transplants on homograft rejection in tumor-bearing mice.
    Rigby PG
    J Lab Clin Med; 1967 May; 69(5):800-9. PubMed ID: 5337458
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Proteus vulgaris lipopolysaccharide on resistance of mice inoculated with tumor cells sensitized to Ehrlich carcinoma transplantation.
    Kato N; Ito S; Yamazaki M; Mizuno D
    Gan; 1973 Apr; 64(2):111-20. PubMed ID: 4124878
    [No Abstract]   [Full Text] [Related]  

  • 13. A spectrophotometric quantitation of cytotoxic action of antiserum and complement by trypan blue.
    Saijo N
    Immunology; 1973 Apr; 24(4):683-90. PubMed ID: 4706564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimentally acquired resistance to tumor transplantation and the rejection of homologous skin transplantation in mice].
    Enoki Y
    Igaku To Seibutsugaku; 1967 Mar; 74(3):185-6. PubMed ID: 4861830
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody formation for malignant tumor. II. Antigenicity of Ehrlich ascites tumor lipoprotein.
    Yamamoto Y; Tadatomo Y; Okamura S
    Acta Med Okayama (1952); 1970 Oct; 24(5):527-36. PubMed ID: 4256471
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of cellular ATP as a measure of cytolytic activity of antiserum.
    Nungester WJ; Paradise LJ; Adair JA
    Proc Soc Exp Biol Med; 1969 Nov; 132(2):582-6. PubMed ID: 5389758
    [No Abstract]   [Full Text] [Related]  

  • 17. Titration of cytolytic antitumor antibody utilizing absorbance at 260 m-mu to measure the leakage of cell constituents.
    Nungester WJ; Adair JA; Allardyce RA; Paradise LJ
    Cancer Res; 1969 Jun; 29(6):1262-6. PubMed ID: 5797109
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunization of mice against Ehrlich ascites tumour using a hamster-Ehrlich ascites tumour hybrid cell line.
    Watkins JF; Chen L
    Nature; 1969 Sep; 223(5210):1018-22. PubMed ID: 4309463
    [No Abstract]   [Full Text] [Related]  

  • 19. [Changes in the immunobiologic properties of Ehrlich ascites carcinoma under the effect of suspension from normal rat tissues. I. Heterotransplantation of Ehrlich ascites carcinoma].
    Novikov DK
    Tsitologiia; 1965; 7(3):420-3. PubMed ID: 5879870
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance and susceptibility to tumours. IV. The temporary survival and rejection of the Ehrlich ascites carcinoma in xenogeneic hosts.
    Dvorák R; Karásek J
    Neoplasma; 1970; 17(4):361-71. PubMed ID: 4394171
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.